Videos

Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.

Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.

Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).

Melanie Goldfarb, MD, MSc, FACS, FACE, FSSO, discusses the importance of survivorship and providing care to patients with thyroid cancer.

Rory Shallis, MD, discusses of the presence of the e-selectin molecule in the bone marrow and how it impacts the marrow microenvironment.

Dr Brian Hill discusses the potential use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma (MCL) and reviews emerging treatment options for patients with MCL.

Anna Jo Bodurtha Smith, MD, discusses her research on insurance mediated disparities in gynecologic oncology.

Alexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.

Robert J. Soiffer, MD, discusses the role of transplant in the post chimeric antigen receptor setting for patients with hematologic malignancies.

Chad Tang discusses where he sees the future of treatment for patients with oligometastatic prostate cancer heading and how the phase 2 EXTEND trial will impact this patient population.

Nitin Jain, MD, discusses the progress of allogeneic chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia and other hematologic malignancies.

Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.

Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.

Wesley Burkett, MD, discusses the next steps for treating patients with endometrial cancer.

Melina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.

Eytan M. Stein, MD, discusses the unmet needs and challenges for treating patients with acute myeloid leukemia.

Dr Neal outlines second-line targeted treatment selection for the patient case, while Lauren Welch, MSN, NP-C, AOCNP, shares her experience with managing the adverse effects of mobocertinib in patients with EGFR exon 20-mutated mNSCLC and comments on potential strategies for treatment modification.

Dr Piotrowska and Lauren Welch offer insight into results interpretation and subsequent treatment decision-making for patients with mNSCLC who are found to harbor an EGFR exon 20 insertion mutation through biomarker testing.

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.

Rana McKay, MD closes by offering actionable advice for community oncologists and considers the potential clinical implications of these and other emerging data.

Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.

Joshua Richter, MD, provides insight on the impact of the addition of daratumumab to treatments for patients with multiple myeloma.

Discussion centered around the unmet needs that the COSMIC-313 trial aims to address, as well as information about included patient populations, study design, and recent conference data.

Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.

Marc S. Ernstoff, MD, discusses metastatic melanoma and how patients may be managed.

Shaji Kumar, MD, discusses the incidence and management of infections in patients receiving teclistamab-cqyv or other bispecific agents for relapsed/refractory multiple myeloma.